Product Information
EVEROLIMUS 0.75 MG TABLET is a generic product labeled by Biocon Pharma Inc., priced at $4.1825 per EA under NDC 70377007111. Its NADAC has been published 48 times since Nov 5, 2025.
FDA first approved this application on Apr 9, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.75 mg/1
Manufacturer
Biocon Pharma Inc.NDC
70377007111
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EVEROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA216140FDA Approved
4/9/2025
TE Code
AB
On Market Since
6/2/2025
Pharmacological Classes
Price Statistics
The NADAC for EVEROLIMUS 0.75 MG TABLET has been published 48 times since Nov 5, 2025, and over the history we have for it it has declined 38.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.1825 per EA |
|---|---|
| All-time high | $8.0069 (Mar 11, 2026) |
| All-time low | $4.1825 (Sep 23, 2026) |
| 52-week high | $8.0069 |
| 52-week low | $4.1825 |
| Median price | $6.5506 |
| Average price | $6.2581 |
| Largest weekly change | -13.9% (Apr 22, 2026) |
| Weeks tracked | 48 |
| Tracking since | Nov 5, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Biocon Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
everolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EVEROLIMUS 0.75 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EVEROLIMUS 0.75 MG TABLET, manufactured by Biocon Pharma Inc., is $4.1825 per EA (NDC 70377007111), effective Sep 30, 2026.
How has the price of EVEROLIMUS 0.75 MG TABLET changed over time?
Over the history we have for it, the NADAC for EVEROLIMUS 0.75 MG TABLET has declined 38.9%. It has been tracked across 48 weekly CMS publications since Nov 5, 2025.
What are the highest and lowest recorded NADAC prices for EVEROLIMUS 0.75 MG TABLET?
Since Nov 5, 2025, the NADAC for EVEROLIMUS 0.75 MG TABLET has ranged from a low of $4.1825 (Sep 23, 2026) to a high of $8.0069 (Mar 11, 2026), with a median of $6.5506 per EA.
Are there cheaper alternatives to EVEROLIMUS 0.75 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as EVEROLIMUS 0.75 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EVEROLIMUS 0.75 MG TABLET?
EVEROLIMUS 0.75 MG TABLET (NDC 70377007111) is labeled by Biocon Pharma Inc., and CMS classifies it as a generic product.